Monday, 21 September 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

ULTIMOVACS Stock Is 21% Up In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of ULTIMOVACS (Oslo Børs All-share Index_GI: ULTI.OL) rose by a staggering 21.16% in 10 sessions from $110.6 to $134.00 at 13:44 EST on Tuesday, after three consecutive sessions in a row of gains. Oslo Børs All-share Index_GI is rising 0.84% to $1,377.27, after successive sessions in a row of losses.

About ULTIMOVACS

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ULTIMOVACS has a trailing twelve months EPS of $-3.98.

Volatility

ULTIMOVACS's last week, last month's, and last quarter's current intraday variation average was 2.18%, 0.84%, and 2.72%.

ULTIMOVACS's highest amplitude of average volatility was 2.18% (last week), 2.05% (last month), and 2.72% (last quarter).

More news about ULTIMOVACS (ULTI.OL).

Categories

stockMarket

Tags

Stock PriceMarket Session NowStock Market NowPrice UpULTIMOVACSMarket SessionStock Price UpULTI.OLStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com